| 1 |
Daley CL, Caminero JA. Management of multidrug-resistant Tuberculosis[J]. Semin Respir Crit Care Med, 2018, 39(3): 310-324.
|
| 2 |
任成山，林 辉，杨仕明. 结核病的流行特征与耐多药的窘迫及其策略[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3): 269-274.
|
| 3 |
成诗明. 我国耐多药结核病防治现状与建议[J]. 中国热带医学，2017, 17(3): 213-215.
|
| 4 |
Nellums LB, Rustage K, Hargreaves S, et al. Multidrug-resistant tuberculosis treatment adherence in migrants: a systematic review and meta-analysis[J]. BMC Medicine, 2018, 16(1): 27.
|
| 5 |
Du Y, Qiu C, Chen X, et al. Treatment outcome of a shorter regimen containing clofazimine for multidrug-resistant tuberculosis: a randomized control trial in china[J]. Clinical Infectious Diseases, 2020, 7(4): 1047-1054.
|
| 6 |
马啸楠，龚军侠，石海萍. 氯法齐明联合二线药物治疗耐多药结核病18个月转阴率、临床疗效及不良反应观察[J]. 中国煤炭工业医学杂志，2019, 22(4): 371-374.
|
| 7 |
World health organization. Position statement on the continued use of the shorter MDR-TB regimen following an expedited review of the STREAM Stage 1 preliminary results. 2018.
|
| 8 |
杨 松，王乐乐，韩 梅，等．世界卫生组织耐药结核病治疗整合指南(2020年版)解读[J]. 国际呼吸杂志，2021, 41(6): 401-409.
|
| 9 |
卢春容，吴清芳，谭卫国，等. 深圳市2016-2018年耐利福平结核病中耐多药结核病分布特征[J]. 中国热带医学，2019, 9(9): 856-859.
|
| 10 |
World Health Organization. Global tuberculosis report 2020.Geneva: World Health Organization, 2020.
|
| 11 |
Yano T, Kassovska-Bratinova S, Teh JS, et al. Reduction of clofazimine by mycobacterial type 2 NADH: quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species[J]. J Biol Chem, 2010, 286(12): 10276.
|
| 12 |
Van Rensburg CE, Joone GK, O′Sullivan JF, et al. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids[J]. Antimicro Agents Chemother, 1992, 36(12): 2729-2735.
|
| 13 |
邝浩斌，谭守勇，梁敏青，等. 耐多药肺结核患者并发气管支气管结核的相关性研究[J]. 中国防痨杂志，2017, 39(3): 242-246.
|
| 14 |
Mothiba MT, Anderson R, Fourie B, et al. Effects of clofazi-mine of planktonic and biofilm growth of mycobacterium tuberculosis and mycobacter[J]. J Glob Antimicrob Resist, 2015, 3(1): 13-18.
|
| 15 |
Parak RB, Wadee AA. The synergistic effects of gamma interferon and clofazimine on phagocyte function: Restoration of inhibition due to a 25 kilodalton fraction from Mycobacterium tuberculosis[J]. Biother, 1991, 3(3): 265-272.
|
| 16 |
桂 敏，陈敬芳，邓国防，等. 氯法齐明治疗耐多药结核病有效性与不良反应的研究进展[J]. 结核与肺部疾病杂志，2021, 2(1): 78-82.
|
| 17 |
马啸楠，龚军侠，石海萍. 氯法齐明联合二线药物治疗耐多药结核病18个月转阴率、临床疗效及不良反应观察[J]. 中国煤炭工业医学杂志，2019, 22(4): 371-374.
|
| 18 |
贺璠．氯法齐明联合方案治疗致耐多药结核病的效果观察[J]. 海峡药学，2020, 32(5): 149-150.
|
| 19 |
Javaid A, Ahmad N, Khan AH, et al. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country[J]. Eur Respir J, 2017, 49(1): 1601967.
|
| 20 |
中国防痨协会临床试验专业分会，《中国防痨杂志》编辑委员会. 氯法齐明治疗结核病的临床应用指南[J]. 中国防痨杂志，2020, 42(5): 409-416.
|
| 21 |
郭 茹，聂文娟，王 隽，等. 抗结核药物的挑战[J]. 临床药物治疗杂志，2018, 16(4): 4-8.
|
| 22 |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版)[J]. 中国防痨杂志，2019, 41(10): 1025-1073.
|
| 23 |
姚 蓉，陆 宇. 抗结核药物早期杀菌活性研究及进展[J]. 中国防痨杂志，2021, 43(7): 724-728.
|
| 24 |
安慧茹，韩怡然，闫梦蝶，等. γ-干扰素联合抗结核药物治疗肺结核临床疗效的Meta分析[J]. 中国防痨杂志，2022, 44(10): 1002-1009.
|
| 25 |
赵 鹏，陈 静，杨光红，等. 住院结核患者抗结核药物性肝损伤的Nomogram风险预测模型构建[J]. 中华结核和呼吸杂志，2022, 69(2): 171-176.
|
| 26 |
Kwonjune JS, Salmaan K, Michael LR. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis[J]. Cold Spring Harb Perspect Med, 2015, 5(9): a017863.
|
| 27 |
Alene KA, Yi H, Viney K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China[J]. BMC Infect Dis, 2017, 17(1): 573.
|
| 28 |
Ansarin K, Sahebi L. Pattern of drug resistant Mycobacterium tuberculosis in the west and northwest of Iran: a meta-analysis[J]. Iran J Microbiol, 2022, 14(3): 285-290.
|